437 results about "Hyperpiesis" patented technology

The present invention relates to methods for the diagnosis and evaluation of cardiovascular illness, particularly stroke, myocardial and other cardiovascular damage damage, hypertension treatment. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for cardiovascular illness or hypertension treatment and one or more non-specific markers for cardiovascular illness or hypertension treatment. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. Algorithms for determining proper treatment are disclosed. A diagnostic kit for a panel of said markers is disclosed. In various aspects, the invention provides methods for the early detection and differentiation of cardiovascular illness or hypertension treatment. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides core-shell compositions and pharmaceutical compositions thereof. Methods of use of the core-shell compositions for therapeutic and / or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of phosphate imbalance disorders, hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.

The invention relates to a method and device for dialysis and or bulk fluid removal by generating a fibrosis chamber within a body cavity and performing dialysis or bulk fluid removal. An implantable medical device is described having a fibrosis chamber and a pump. A dialysis chamber and an optional electrodialysis unit can further be provided. An additional controller uses sensory feedback to regulate the fluid levels by altering the extracellular fluid retention within the fibrosis chamber. This device can be used for the treatment of patients with chronic kidney disease who may also be suffering from cardiorenal syndrome and hypertension.

Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

The invention relates to a health-care tea and relative technique, which uses hemp seed and sweet tea as basic materials, assisted with other natural Chinese medicine drug, to be used on various diseases. The inventive health-care tea combines the characters of food, health-care product and drug, with good taste, and treatment on hypertension, hyperlipemia, high cholesterol and constipation, without side effect.

Preferred embodiments of the present invention are related to novel therapeutic drug combinations and methods for treating and / or preventing hypertension and complications in patients with diabetes and / or metabolic syndrome. More particularly, aspects of the present invention are related to using a combination of cicletanine and a second antihypertensive agent (preferably a calcium antagonist, an ACE inhibitor, or an angiotensin II receptor antagonist) for treating and / or preventing hypertension and complications in patients with diabetes and / or metabolic syndrome.

Sustained release oral solid dosage forms comprising agglomerated particles of a therapeutically active medicament in amorphous form, a gelling agent, an ionizable gel strength enhancing agent and an inert diluent, as well as processes for preparing and using the same are disclosed. The sustained release oral solid dosage forms are useful in the treatment of hypertension in human patients.

The present invention relates to a method for the prophylaxis of vascular headaches which do not originate from hypertension, especially migraine, the method comprising administration of telmisartan to a subject in need of such a treatment. The present invention relates also to a method for the prophylaxis of vascular headaches, comprising the co-administration of telmisartan in combination with other drugs suitable for migraine prophylaxis and / or acute treatment of migraine.

A therapeutic vibrational system for treating such conditions as hypertension may have a plurality of vibrating patches; each including a vibrating motor with an adhesive for application to a person's skin permitting the plurality of vibrating patches to be placed in two or more locations on the person's skin, as well as a controller with a user interface and configured to provide control instructions to the plurality of vibrating patches.

The invention relates to compositions comprising a sodium channel inhibitor. Also provided are methods of identifying such inhibitors, as well as kits and pharmaceutical compositions containing the same. The invention also relates to methods of treating disorders associated with irregular or improper epithelial sodium channel ("ENAC") activity, including hypertension, renal insufficiency, electrolyte imbalances, cystic fibrosis, and Liddle's syndrome.

The invention provides a composition, a drug, a food additive and a food, which comprises ground lotus and / or a lotus extract and a lactic acid bacterium. The composition, drug, food additive and food of the invention can be used to relieve and treat constipation, excessive sensitivity to cold, hemorrhoid, ear ringing, menopausal syndrome, hypertension and menstrual disorder.

The invention the invention relates to a capsule for treating hyperpiesis and apoplexy and a preparation method thereof. The capsule comprises the active ingredients made of the raw materials based on parts by weight: 6-12 parts of scorpion, 4-8 parts of centipede, 9-20 parts of the larva of silkworm with botrytis, 4-10 parts of leech, 6-12 parts of earthworm, 15-40 parts of turtleback, 20-30 parts of radix puerariae, 30-90 parts of radix astragali, 9-12 parts of peach kernel, 9-12 parts of safflower, 9-12 parts of angelica, 9-12 parts of szechuan lovage rhizome, 9-15 parts of red paeonia, 9-15 parts of notoginseng, 9-20 parts of salvia miltiorrhiza, 20-40 parts of prepared rhizome of rehmannia, 9-15 parts of rhizoma gastrodiae and 15-30 parts of uncaria. The raw materials are sliced, dried, crushed, extracted, concentrated, dried, processed by ball milling and filled in the capsule. The capsule can be used for treating hyperpiesis, apoplexy and coronary heart disease, and the preparation method is simple and easy to implement.

A method of treating or preventing one's health problem that are associated with one's cells having a poor metabolic capability to process fat includes ingesting a therapeutically effective dosage of an anaplerotic precursor. Examples of such health problems include obesity and the related health conditions that are aggravated by obesity, diabetes, hypertension, atherosclerosis, migraines and headaches, menstrual cramps, cholesterol excesses, multiple sclerosis and Alzheimer's disease, anemia, high blood uric acid levels, ketosis, tobacco and other drug addictions, and digestive problems. In a preferred embodiment, this method includes the daily ingestion of L-aspartic acid, or a pharmaceutically acceptable analog thereof, at the rate of 10-14 g / day and restricting from one's diet the intake of starchy foods.

An application of an invented medicinal composition in preparing the medicines for treating primary hypertension and protecting heart and kidney is disclosed.

The present invention is a synthetic microfluidic microvasculature network and associated methods. The synthetic microfluidic microvasculature network mimics the structure, fluid flow characteristics, and physiological behavior of physiological microvasculature networks. Computational methods for simulating flow and particle adherence in synthetic and physiological microvascular systems and methods for determining parameters influencing particle adhesion and drug delivery are also described. The invention has many uses including the optimization of drug delivery and microvascular treatments and in describing disease mechanisms that affect the microvasculature such as inflammation, diabetes and hypertension.

Provided herein are Aminopurine Compounds having the following structure: (I) wherein R<1 >, R<2> and and R<3> are as defined herein, compositions comprising an effective amount of an Aminopurine Compound and methods for treating or preventing cancer, a cardiovascular disease, a renal disease, an autoimmune condition, an inflammatory condition, macular degeneration, ischemia-reperfusion injury, pain and related syndromes, disease-related wasting, an asbestos-related condition, pulmonary hypertension or a condition treatable or preventable by inhibition of the JNK pathway comprising administering an effective amount of an Aminopurine Compound to a patient in need thereof.

A renin inhibitor comprising a compound represented by the formula:wherein each symbol is as defined in the description, or a salt thereof or a prodrug thereof. The compound of the present invention has a superior renin inhibitory activity, and thus is useful as an agent for the prophylaxis or treatment of hypertension, various organ damages attributable to hypertension and the like.

The disclosure provides methods for treating, preventing, and reducing risk of occurrence of renal insufficiency in mammals. The disclosed methods include administering to a subject susceptible to, or afflicted with, renal disorder therapeutically effective amounts of a TGF-β antagonist and a renin-angiotensin-aldosterone system (RAAS) antagonist so as to maintain desirable levels of renal function. The populations treated by the methods of the invention include but are not limited to patients suffering or at risk for the development of renal insufficiency, such as those afflicted with type I or type II diabetes, hypertension, (auto)immune disease, systemic fibrosis, etc.

A health-care food for preventing and treating atherosclerosis, hypercholesterolemia, hyperlipemia, hypertension, coronary heart disease, angina pectoris, tumor, etc, and balancing the functions of organs is prepared from 10 Chinese-medicinal materials including anemarrhena rhizome, ginger, wolfberry fruit, yam, etc.

The invention relates to methods and compositions for identifying subjects having, or predisposed to having, gestational diabetes, preeclampsia, and gestational hypertension. The methods are applicable to urine and / or blood samples and can be conducted prior to the third trimester of pregnancy.

The invention relates to a traditional Chinese medicine for treating hyperpiesis and a preparation method, the medicine can effectively treat hyperpiesis and has double efficacy of herbal cuisine and diet therapy in treating hyperpiesis. The invention comprises the following bulk drugs: 10-45 of propolis powder, 9-40 of natto powder, 9-40 of wild jujube seed, 9-40 of gastrodia tuber, 8-30 of corn stigma, 8-30 of cassia seed, 8-25 of pagodatree flower powder, 8-25 of kudzuvine root, 5-15 of gambir plant, 5-15 of scutellaria laterifolia, 5-15 of haw, 2-10 of apocynum, 2-10 of earthworm, 2-10 of evodia fruit, 8-25 of selfheal, 5-15 of Chinese gentian root, 5-15 of antelope horn, 5-15 of bupleurum, 5-15 of red-rooted salvia, 2-10 of radish seed and 2-10 of Chinese magnoliavine, wherein the unit of weight is parts by weight.

A Chinese medicine for treating hypertension and its complications is prepared from 7 Chinese-medicinal materials including pueraria root, chrysanthemum flower, cassia seed, haw, etc. Its preparing process is also disclosed.

The present invention relates to a Chinese medicine capsule preparation for effectively curing hypertension and coronary heart disease. Said capsule preparation is made up by using 14 Chinese medicinal materials of gastrodia root, uncaria stem and thorn, chrysanthemum flower, tortoise plastron, lyceum berry and others and adding nifedipine through a certain preparation process.

Compositions and methods are disclosed for decreasing the amount and activity of matrix-degrading metalloproteinases (MMPs) in and around cells. The compositions and methods are useful for treating and / or preventing symptoms of diseases including but not limited to Hypertension, Type II Diabetes, and Metabolic Syndrome X. Such treatment is effected by normalizing the blood plasma's protease activity, reducing blood pressure, preventing membrane receptor cleavage, and reducing the levels of insulin resistance and oxygen free radicals in the blood stream.

The present invention relates to the prognosis and risk assessment in pregnant women to develop pregnancy-induced hypertension and / or preeclampsia by the determination of marker levels.

A glycoprotein extracted from the fruiting body of Grifola frondosa is demonstrated to have antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects, and has great potential as an active component for pharmaceuticals, dietary supplements or health food preparations to treat and / or prevent the above diseases. This invention is to provide the glycoprotein and its preparation method.

The invention discloses the ingredients and the preparation method of an oral pulse pellet pharmaceutical preparation of metoprolol salts. The pharmaceutical preparation is a multi-layered coated pellet which has a basic structure of an immediate-release pellet core, an alkaline layer and a retardation layer containing remedium cardinale of 20 to 100 mg from inside to outside, wherein, the retardation layer contains polyacrylic resin 3, the weight increment of which is 100 to 240 percent of the immediate-release pellet core; the alkaline layer is a medicinal inorganic alkaline adjuvant, the weight of which is 10 to 30 percent of the immediate-release pellet core. After being taken, the pulse pellet begins to release immediately till a complete release is obtained after a time lag of 3 to 4 hours and achieves the effect of one pulse release. The oral pulse pellet pharmaceutical preparation can effectively prevent angina pectoris, hyperpiesis and other diseases from being triggered due to the rise of blood pressure and heart rate within a few hours after a patient awakens and wakes up in the early morning.